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The tumor microenvironment (TME) is a multi-faceted cellular environment that both 1 constrains the evolving tumor (Hanahan and Coussens, 2012) and plays a pivotal role in tumor 2 progression and therapeutic response (Junttila and de Sauvage, 2013) . Existing experimental 3 methods to characterize the TME, such as imaging and single-cell based approaches, cannot 4 be applied retrospectively to existing large-scale bulk tumor datasets, representing a vast and 5 mostly unexplored resource for studying cancer cell ligand-receptor repertoires and cross-talk 6 in the. Existing approaches to deconvolve bulk tumor gene expression profiles have mainly 7 focused on estimation of cell type fractions (Aran et al., 2017; Newman et al., 2015) or have 8 been optimized or tested on a limited set of tumor types (Ahn et Previous studies have analysed tumor purity in a pan-cancer context (Aran et al., 2015) 11 and developed regression-based methods for accurate mixed-tissue transcriptome 12 deconvolution (Shen-Orr et al., 2010). Here we combined these approaches to estimate 13 cancer and stromal (comprising any non-cancer cell) compartment molecular profiles from 14 bulk tumor RNA-seq data and infer signaling interactions between average representative 15 cells in these two compartments. Uniquely, our approach (TUMERIC) avoids making 16 assumptions about the transcriptional profiles of cancer and stromal cells in a given tumor by 17 integrating independent estimates of tumor purity derived from DNA sequencing and copy 18 number profiling data. We validate the approach using public cancer genomics data, mass 19 spectrometry protein abundance data, single cell RNA-seq data, and immunohistochemistry 20 imaging data. We apply the method to ~8000 tumor samples across 20 solid tumor types from 21
The Cancer Genome Atlas (TCGA) to infer cancer and stromal cell crosstalk conserved across 22 tumor types as well as tissue specific interactions. Finally, we compare cross talk across the 23 molecular subtypes of breast cancer and infer signaling interactions specific to the aggressive 24 basal subtype. 25
27
Results 1
Overview of approach 2
We first estimate the cancer cell fraction (tumor purity) from somatic mutation allele 3 frequencies, DNA copy number profiles, and mRNA expression signatures of the tumors using 4 a robust consensus approach (Fig. 1 and Methods) . The tumor transcriptome profiles are then 5 deconvolved into an average cancer and stromal cell profile using non-negative linear 6 regression. To infer cancer and stromal cell ligand and receptor repertoires, as well as 7 potential crosstalk between these compartments, we combine the inferred expression profiles 8 with a curated database of ligand-receptor (LR) interactions (Ramilowski et al., 2015) to 9 estimate relative LR complex concentrations under equilibrium (Methods). 10 11
Estimation of tumor purity across 8000 tumor samples 12
To analyze crosstalk in a pan-cancer context, we first estimated tumor purities of ~8000 13 samples across 20 solid tumor types from TCGA. Briefly, we obtained purity estimates based 14 on DNA somatic variant allele frequency (PurBayes and AbsCN-seq), copy number (ASCAT), 15 and mRNA expression (ESTIMATE) data using four existing algorithms, followed by 16 imputation and quantile normalization, to produce robust consensus tumor purity estimates 17 across all sample. Most tumors had a purity in the range 40-70%, but there was large variation 18 within and between tumor types ( Fig. 2a, Suppl. Fig. 1 ). Pancreatic adenocarcinoma (PAAD) 19 tumors had very low purity (median ~39%), consistent with previous observations (Wood and 20 Hruban, 2012). The glioblastoma (GBM) and ovarian cancer (OV) samples had the highest 21 purity estimates, likely influenced by sample selection bias in the first phase of the TCGA 22 project. 23
We found that previously published consensus tumor purity estimates (Aran et al., 24 2015) , while positively correlated with TUMERIC estimates, were likely overestimating purity 25 by >30% as compared to genome-derived purity estimates (Suppl. Fig. 1 ). We then compared 26 TUMERIC consensus purity values with purity estimates from recently published 27 transcriptome deconvolution methods, using tumor purity estimates computed by the TCGA 28 pan-cancer consortium (ABSOLUTE method) as an independent benchmark (Hoadley et al., 29 2018) . One method (CiberSortX) could only be applied in three tumor types because it 30 required a tumor type specific signature matrix for deconvolution. Another method (DeMixT) 31 could only be applied in tumor types where matched normal tissue samples were available. 32
Overall, the concordance with ABSOLUTE purity was generally low for the three tested 33 transcriptome deconvolution methods (Pearson r > 0.4 in only 2/8 tested tumor types, Figure  34 2c). Furthermore, all methods failed (r < 0.15) to estimate tumor purity in at least two of the 35 4 tested tumor types. In contrast, TUMERIC consensus purity estimates were generally highly 1 correlated (r > 0.75 in 6/8 tumor types, lowest r = 0.42 for THCA) with TCGA ABSOLUTE 2 purity estimates across cancer types. 3 4
Validation of approach 5
We performed multiple analyses to evaluate the accuracy of TUMERIC in deconvolution of 6 cancer and stromal compartment transcriptomes. Firstly, known stromal (FAP, CD3D, CD4, 7 CSF1R) and epithelial-cell specific factors (EPCAM) showed expected strong and consistent 8 gene expression differences between stromal and cancer compartments across cancer types 9 (Suppl. Fig. 2-6 ). Next, since somatic copy number alterations (CNAs) are hallmarks of cancer 10 cell genomes, we reasoned that genes expressed exclusively in the stromal compartment 11 should not be affected by tumor CNAs. We used TUMERIC to infer the top-100 cancer and 12 stromal-cell specific genes in each tumor type. The cancer-specific genes in each tumor type 13 were distributed widely across the genome (Suppl. Fig. 17 ). We found strong correlation 14 between bulk tumor CNA and expression of cancer-specific genes, but no correlation between 15 tumor CNA and expression of stroma-specific genes (Fig. 3a ). Variation in correlation between 16 tumor types could be explained by the overall prevalence of CNAs in a given tumor type, 17
where tumor types with higher levels of chromosomal instability showed higher correlation of 18 tumor CNA and expression of cancer-specific genes ( Fig. 3a) . Similarly, as a positive control, 19
we found that previously derived stromal and immune-cell specific genes (Yoshihara et al., 20 2013) were inferred by TUMERIC to have markedly higher expression in the stroma 21 compartment of all tumor types ( Fig 3b) . 22
To test the concordance of TUMERIC with tumor single-cell RNA-seq (scRNA-seq) 23 profiling, we analyzed TUMERIC expression estimates for cancer and stromal-cell specific 24 genes identified by scRNA-seq of melanoma tumors (Tirosh et al., 2016) . TUMERIC inferred 25 significantly higher stroma-compartment expression for scRNA-seq stromal-cell specific 26 genes (P=2e-55, Mann Whitney, two-tailed), and significantly higher cancer-compartment 27 expression for cancer-cell specific genes (P=3.6e-4, Fig. 3c ). Next, using gene set enrichment 28 analysis, we found consistent association of compartment-wise inferred gene expression and 29 known hallmarks of cancer (e.g. cell cycle and DNA repair) and stromal cells (e.g. 30 angiogenesis and immune response) across cancer types ( Fig. 3d , Suppl. Fig. 7 ). We then 31 evaluated the extent that the deconvolved mRNA profiles represent an accurate proxy for 32 protein levels in the cancer and stromal cells. We used TUMERIC to deconvolve protein 33 abundance data from two TCGA tumor types (Edwards et al., 2015) , and found strong 34 concordance between the mRNA and protein expression profiles (Fig 3e) . Finally, to test the 35 5 concordance of TUMERIC with immunohistochemistry (IHC) data, we identified genes with 1 high variability of cancer and stromal cell differential expression across tumor types and used 2 IHC data from The Human Protein Atlas (Uhlen et al., 2017) to confirm that expression 3 patterns of two such genes were indeed variable and concordant across tumor types ( Fig 3f  4 and Suppl. Fig 8) . Although this IHC comparison is limited to two genes, the combined 5 concordance of transcriptome deconvolution data with both proteomic and IHC data supports 6 an overall concordance between transcriptome and protein-level data. Overall these diverse 7 comparisons with orthogonal types of data support that TUMERIC can robustly deconvolve 8 gene expression profiles of cancer and stromal cell compartments across the 20 tested tumor 9 types. 10 11
Compartment specific expression of ligands and receptors 12
To explore ligand-receptor (LR) signaling across cancer types, we focused on 263 ligands and 13 242 receptors (603 LR pairs) with detectable bulk tumor gene expression (>1 RPKM in >25% 14 of samples) in at least half of the 20 cancer types. We first analyzed for compartment 15 specificity of these ligands and receptors. Expectedly, ligands belonging to the complement 16 system (e.g. C1QB and C3) as well as leukocyte specific chemokines (e.g. CCL5 and CCL21) 17 had high stroma specific expression across tumor types ( Fig 4a) . Cancer-specific ligand 18 expression across tumor types was much less frequent and pronounced. Among the most 19 common cancer-specific ligands were endothelial cell targeting factors (PODXL2 and 20 VEGFA), consistent with the hypothesis that cancer cells interact with and induce tumor 21 vascularization. Immune (e.g. CD2 and CD4) and macrophage cell (CSF1R) specific factors 22 were expectedly among the top stromal specific receptors across tumor types ( Fig 4b) . Similar 23 to ligands, receptors with cancer-cell specific expression across tumor types were less 24 common. The top common cancer specific receptors included known cancer associated 25 members of the EGF-family (ERBB2 and ERBB3), Wnt-family (LRP4, LRP5 and LRP6), and 26 FGF-family (FGFR3). In summary, these data underline that our approach is able to tease 27 apart cancer and stromal-compartment specific expression of ligands and receptors from bulk 28 tumor transcriptome profiles. 29 30
Recurrence of ligand-receptor interactions across tumor types 31
Next, we developed the Relative Crosstalk (RC) score to quantify and differentiate between 32 types of autocrine and paracrine (here denoting signaling within or between compartments, 33 respectively) ligand-receptor (LR) crosstalk (Fig 4c and Suppl. Table 1 ). We first evaluated the 34 extent that known LR pairs had consistent crosstalk directionality across tumors types and 35 6 found a striking difference between the cancer and stromal compartment. While only 3 LR 1 pairs had strong autocrine cancer signaling scores (median RC score > 40%) across tumor 2 types, 264 LR pairs showed strong autocrine stroma signaling RC scores across cancer types 3 ( Fig 4d) . This suggests that, in solid tumors, autocrine cancer signaling tends to be tumor type 4 specific and determined by the cancer cell-of-origin. In contrast, stromal autocrine signaling is 5 often conserved and independent of tumor type and tissue. Interestingly, the paracrine 6 signaling interface between cancer and stromal cell compartments also had a high number of 7 recurrent interactions (26-40 conserved interactions, respectively), highlighting the importance 8 of the tumor environment on cancer cell biology. 9
Inferred recurrent cancer-cell autocrine LR pairs included receptors such as FGFR8, 10 LRP6 and MST1R (Fig. 4e ). Signaling through ACVR2B was notably both among the top 11 inferred cancer autocrine and stroma-to-cancer signaling interactions across tumor types ( Fig  12   4e ,g), highlighting a common role for ACVR-coupled TGF-beta/SMAD signaling in 13 tumorigenesis. We analyzed recurrent cancer-to-stroma LR interactions to investigate how 14 cancer cells may engage and shape their microenvironment (Fig 4f) . Top inferred cancer-to-15 stroma interactions included the lymphocyte-specific selectin (PODXL2-SELL), highlighting a 16 possible conserved interaction between cancer cells and leukocytes or endothelial cells 17 (Fieger et al., 2003) (only the leukocyte-specific selectin (SELL) was abundantly expressed 18 across most tumors and included in our analysis). 19 20 PD-1 and CTLA-4 immune checkpoint ligands are overexpressed in stromal cells 21
The top recurrent stroma-stroma interactions included many chemokine signaling interactions, 22 especially involving CXCR3 and CXCR5 receptors, suggesting common stroma induced 23 recruitment of leukocytes and lymphocytes to solid tumors (Suppl. Fig 9) . Interestingly, the top 24 recurrent stromal interactions also included the known immune checkpoint interactions 25 CD86/CTLA-4 (CD86/CTLA4) and PD-L2/PD-1 (PDCD1LG2/PDCD1). The known PD-L1/PD-26 1 (CD274/PDCD1) checkpoint interaction was not among our initial curated and analyzed 27 ligand-receptor interactions, but a follow-up analysis of this LR pair revealed a similar stroma-28 stroma enriched cross-talk pattern (median stroma-stroma RC=87%). Interestingly, 29 expression levels of immune checkpoint ligands (PD-L1, PD-L2, CD86) were highest in stroma 30 across all tumor types. This suggests that the bulk of immune checkpoint inhibitory signals in 31 the tumor microenvironment may be mediated by non-cancer cells. However, some tumor 32 types showed moderate to high expression of especially PD-L1 and CD86 in cancer cells. 33 Glioblastoma (GBM) was the tumor type with highest expression of both CD86 and PD-L2 in 34 both stroma and cancer cells. In contrast, brain tumors (GBM and LGG) also had the lowest 35 7 stromal expression of both the CTLA-4 and PD-1 receptor as compared to all other tumor 1 types, highlighting potential differences in T-cell infiltration levels, activation states, or 2 dynamics of checkpoint inhibition in brain tumor tissue. 3 4
Expression of immune checkpoints and response to immune checkpoint inhibition 5
Expectedly, inferred gene expression of the two checkpoint receptors, PD-1 and CTLA-4, was 6 high in stroma and almost absent in cancer cells (Fig. 4h ). Stromal expression of these two 
Convergence of autocrine cancer cell crosstalk across tumor types 21
The pan-cancer analysis indicated that cancer-cell directed LR interactions tended to differ 22 across tumor types. We therefore searched for LR interactions with extreme autocrine RC 23 scores in individual tumor types. Indeed, we found that most (14/20) cancer types had multiple 24 LR interactions with high cancer autocrine scores (RC score > 60%, Fig 4i) . Interestingly, the 25 top autocrine cancer-cancer LR interactions tended to converge on the same signaling 26 pathways. 9/20 solid tumor types had (among top-2, Fig 4i) autocrine interactions converging 27 on TGF-beta and SMAD signaling pathways (BMP and ACVR-receptors). 8 tumor types had 28 interactions involving different fibroblast growth factor ligands and receptors, and 6 tumor 29 types had interactions converging on Eph/ephrin signaling. These results suggest that cancer 30 cells of solid tumors may often be dependent on autocrine activation of these signaling 31 pathways, and our data highlight specific LR candidate interactions associated with this 32 activation in each tumor type. 33
34
Validation of compartment-specific ligand-receptor expression using scRNA-seq data 8 We next investigated compartment-specific expression of candidate ligand-receptor pairs 1 using a melanoma scRNA-seq dataset (Tirosh et al., 2016) . Firstly, we analyzed the 3 pan-2 cancer cancer-to-cancer pairs with highest inferred cancer-cancer signalling in SKCM (BMP7 3 > ACVR2B, BMP8B > ACVR2B, WNT3 > LRP6, Fig 4e) . Among these pairs, the two receptors 4 (ACVR2B and LRP6) were inferred to be overexpressed in cancer cells (~4-fold higher 5 expression) and ligands were inferred to have unaltered expression in SKCM (Suppl. Table  6 1). We then compared the expression of the 2 receptors in malignant and non-malignant cells 7 as inferred by the authors (Tirosh et al., 2016) . Confirming our results, both receptors were 8 significantly overexpressed in the cancer compartment (P <1e-10, Wilcoxon rank-sum, Suppl. 9 Fig. 16 ). Next, we analysed the top 2 inferred SKCM cancer autocrine pairs (BMP7 > 10 BMPR1B, SEMA6A > PLXNA2, Fig. 4i ). Within each of these two pairs, the receptor BMPR1B 11 and the ligand SEMA6A were inferred to be significantly overexpressed in cancer cells (4 and 12 7-fold, respectively, Suppl. Table 1 ). Confirming our results, both of these genes were also 13 significantly overexpressed in cancer cells of the melanoma RNA-seq dataset (P <1e-10, 14
Suppl. Fig. 16 ). 15
16
Autocrine and paracrine crosstalk in brain tumors 17
The two brain tumor types (LGG and GBM) were both characterized by very high autocrine 18
Delta-Notch signaling scores (DLL1-NOTCH1, RC > 80%, Fig 4i) . Both DLL1 and NOTCH1 19 were inferred to have >4 fold higher expression in cancer compared to tumor stromal cells and 20 normal brain tissue in both tumor types. DLL1 cancer cell expression was ~16-fold higher than 21 stroma and normal tissue in LGG (Suppl. Fig 10) . These data are consistent with previous 22 studies showing that Notch autocrine/juxtacrine signaling is critical for glioma tumorigenesis 23 (Purow et al., 2005; Teodorczyk and Schmidt, 2015) . 24
In contrast to autocrine cancer cell signaling, stroma-to-cancer crosstalk is lost when 25 cancer cells are cultured in vitro. Interestingly, the top-2 stroma-to-cancer specific interactions 26 for glioblastoma (GBM) converged on EGFR (Suppl. Fig 11) . EGFR is a well-studied 27 oncogene in GBM where 40-50% of patient tumors have EGFR overexpression driven by gene 28 amplification (Brennan et al., 2013) . We inferred >30-fold higher EGFR expression in GBM 29 cancer cells compared to the stromal compartment and normal brain tissue (Suppl. Fig 11) . In 30 contrast, all canonical EGFR ligands were expressed at highest levels in the stroma (Suppl. 31 Fig 11) . SPINK1 and AREG ligands were inferred to be exclusively expressed in stroma, and 32 the most abundant ligand, EFEMP1, had ~8-fold higher expression in the stromal 33 compartment compared to cancer cells and normal brain tissue. A similar pattern was 34 observed in lower grade gliomas (LGG) (Suppl. Fig 11) , suggesting that EGFR signaling in 35 9 glioma and glioblastoma cancer cells is driven mainly by ligands produced by the tumor 1 infiltrating stroma. These data are also consistent with the observation that glioblastoma 2 cancer cells rapidly loose EGFR amplifications during cell culture (Pandita et To investigate whether TUMERIC could identify differences in crosstalk between subtypes of 7 a given tumor type, we inferred cross-talk associated with basal-like triple-negative breast 8 cancers (TNBCs), a more aggressive subtype of breast cancer that generally do not 9 overexpress HER2 and estrogen receptors. Expectedly, cancer cells of basal tumors had ~60-10 fold and 250-fold lower expression of HER2 (ERBB2) and estrogen (ESR1) receptors as 11 compared to cancer cells of HER2+ and Luminal subtypes, respectively (Suppl. Figure 12 ). 12 NOTCH1 receptor expression was elevated in cancer cells of basal tumors, with MFAP2 and 13 JAG1 as the top autocrine and paracrine specific ligands, respectively (Fig 5a- Table  14 1). Consistent with this observation, cancer cells of basal tumors showed gene expression 15 signatures of notch pathway activation relative to non-basal tumors (Suppl. Figure 13 ). Cancer 16 cells of basal tumors also showed upregulated FZD7 receptor expression and enrichment of 17 autocrine WNT11 and autocrine/paracrine WNT3 interactions. Gene set enrichment analysis 18
indicated an overall enrichment for activation of WNT/beta-catenin signaling in cancer cells of 19 basal tumors (Suppl. Figure 13 ). Interestingly, the Frizzled/Wnt ligand antagonist, SFRP1, was 20 inferred to have high expression in cancer cells of basal tumors while being nearly absent in 21 cancer cells of other breast cancer subtypes (Fig 5c) . At the receptor tyrosine kinase interface, 22 cancer cells of basal tumors were characterized by increased KIT and decreased RET 23 signaling compared to non-basal tumor types. Our analysis also inferred strong up-regulation 24 of IL-6 signaling through GP130 (IL6ST) in cancer cells of non-basal tumors. 25
Next, we wanted to validate the TUMERIC predicted differential expression of SFRP1 26 and IL6ST in the cancer cells of basal versus luminal breast cancer subtypes. We performed 27 RNA in situ hybridization (ISH) using specific RNAScope probes generated against either 28 SFRP1 or IL6ST in FFPE sections of breast tumors from each subtype (see Methods, Fig 5d) . 29
Cancer cell mRNA expression in each subtype was quantified using two different approaches 30 yielding similar results (Fig 5e and Suppl. Fig 14) . Remarkably, and consistent with the 31 TUMERIC prediction, we observed higher expression of SFRP1 in the cancer cells of the basal 32 subtype, compared to the luminal tumors (Fig 5e) . In contrast, IL6ST had lower expression in 33 cancer cells of the basal tumors as compared to the luminal subtype. 34
Overall, these data highlight putative differences in crosstalk of basal and non-basal 1 breast cancer tumors and demonstrates how our approach can be applied to study cell 2 signaling associated with specific molecular, genetic, or clinical subtypes of tumors. 3 4 5 Discussion 1
Tumors are heterogenous mixtures of cancer cells and infiltrating non-cancer (stromal) cells. 2 Molecular measurements obtained from a bulk tumor sample reflect an average across these 3 components. By chance, the composition of these components will vary across tumor 4 samples, introducing noise for downstream integrative analysis. However, in this study we 5 demonstrate how this variability also enables inference of (average) cancer and stromal cell 6 gene expression profiles across a collection of tumor samples. Our approach, TUMERIC, uses 7 genomic data to first produce unbiased tumor purity estimates followed by constrained 8 regression to deconvolve the matched bulk tumor transcriptome profiles. We show that this 9 approach consistently recovers known hallmarks of cancer and stromal cell transcriptomes 10 and is concordant with orthogonal single cell transcriptome and immunohistochemistry 11 imaging data. The general methodology is in theory not restricted to transcriptomic data and 12 might be used to deconvolve other types of bulk tumor molecular data such as proteomic ( Fig  13   3e ) or epigenetic profiles. 14 By applying the method to ~8000 tumor samples across 20 solid tumors, we inferred 15 ligand and receptor expression profiles in cancer and stromal cells across tumor types (Suppl. 16 Table 1 ). We then nominated potential crosstalk within and between cancer and stromal 17 compartments across tumor types. A large number of crosstalk interactions were inferred to 18 be highly stroma specific across all tumor types. These interactions included many chemokine 19 interactions as well as therapeutically important PD-1 and CTLA-4 immune checkpoint 20
interactions. Checkpoint receptors were expectedly exclusively expressed in stromal cells. 21
However, we inferred substantial expression of especially PD-L1 and CD86 ligands in the 22 cancer cells of many tumor types, consistent with the hypothesis that cancer cells can express 23 these ligands to attenuate T-cell responses (Sharma and Allison, 2015) . Unexpectedly, most 24 tumor types showed even higher expression of these checkpoint ligands in the stromal 25 compartment, suggesting that the bulk of immune checkpoint inhibitory signals in the tumor 26 microenvironment may be mediated by non-cancer cells. Interestingly, the tumor types with 27 highest (e.g. lung squamous and kidney cancers) and lowest (e.g. colorectal cancer) inferred 28 PD-L1 cancer cell expression have markedly different response rates to PD-L1/PD-1 29 checkpoint inhibition in clinical trials (Yarchoan et al., 2017) . Further studies are however 30 needed to explore the hypothesis that bulk tumor deconvolution of immune checkpoints can 31 provide novel insights into the conditions for effective immune checkpoint therapy. these observations are consistent with our data and suggest that our methodology and data 27 could help design in vitro assays and co-culture models that more accurately mimic the biology 28 of the human TME. 29 Furthermore, we demonstrate that TUMERIC can nominate differences in crosstalk 30 between molecular or clinical subtypes of a given tumor type. By inferring crosstalk specific to 31 basal breast cancers, we recovered the expected patterns for HER2 and estrogen receptor 32 expression across breast cancer subtypes. We inferred specific Notch and Wnt autocrine 33 cancer cell signaling interactions specific to basal tumors. Interestingly, the Wnt inhibitory 34 ligand, SFRP1, was inferred to have very high expression in cancer cells of basal tumors while 35 being nearly absent in cancer cells of other breast cancer subtypes (Fig 4d) . Downregulation 1 of SFRP1 has been linked to epithelial to mesenchymal transition (EMT) in breast cancer cells 2 (Scheel et al., 2011) , indicating potential differences in EMT pathways or states between 3 luminal and basal breast cancer cells. Interestingly, our analysis also inferred strong up-4 regulation of IL-6 signaling through GP130 (IL6ST) in cancer cells of non-basal tumors, 5 consistent with previous studies highlighting a functional role for RET-IL6 crosstalk in ER-6 positive breast tumors (Gattelli et al., 2013) . Importantly, we could validate the predicted 7 subtype specific expression of SFRP1 and IL6ST (GP130) using RNA-ISH in breast cancer 8 FFPE tissue sections. Overall, these data suggest that tumor subtypes can have profound 9 differences in crosstalk, and our analysis can provide a list of putative, testable interactions 10 underlying breast cancer subtypes. 11
We note that a key limitation of our approach is that local concentrations of ligands 12 and receptors may differ considerably from our average compartment-level estimates. While 13 this is especially important when considering between-compartment crosstalk, it likely matters 14 less for the inference of cancer-to-cancer autocrine signaling (where the same cell produces 15 the interacting ligand and receptor). We expect future high-throughput technologies such as 16 sample-level spatial transcriptomics could be combined with our cohort-scale approach to 17 provide a more accurate and comprehensive description of tumor crosstalk. 18
Overall, our study provides unique insights into the complex interactions shaping the 19 TME. Our approach is especially useful in settings where bulk tumor biopsy data is either 20 already abundant or the only feasible data source, which is the case in many clinical settings. 21
We anticipate that the method could complement existing biomarker and target discovery 22 approaches by providing computationally purified molecular profiles of cancer cells as they 23 exist inside human tumors. to the TCGA RNA-seq (log2 FPKM) data. In order to derive consensus tumor purity estimates, 14
we carried out missing data imputation followed by quantile normalization separately for each 15 cancer type. Some tumor purity values were missing because the algorithms failed to 16 converge on certain input data. Additionally, we observed some instances of very high (>98%) 17 or low (<10%) purity estimates, but such cases were usually only found by a single method 18 for a given tumor and were therefore also assigned as missing data. Missing data was then 19 imputed using an iterative Principal Component Analysis of the incomplete algorithm-vs-20 sample tumor purity matrix (using the missMDA R package(Josse and Husson, 2016)). We 21 used quantile normalization to further align and standardize the tumor purity distributions of 22 different algorithms per tumor type. Briefly, a mean reference purity distribution is computed 23 and these mean values are substituted back into the purity distributions of the individual 24 algorithms. Since ESTIMATE generated purity estimates with a large bias compared to the 25 other three methods (generally 30-50% higher, Suppl. Fig 1) , we did not use ESTIMATE purity 26 values to compute the mean reference distribution (see code in Supplementary Data). The 27
final TUMERIC consensus tumor purity estimate was obtained as the mean of these 28 normalized purity values. were executed on 100 randomly selected tumor transcriptome samples from each tumor type. 36
The datasets were normalized and parameters were set according to authors instructions (see 37
Supplementary Methods). CiberSortX could only be run for tumor types where a compatible 1 signature matrix was available (HNSC, LUAD, and LUSC), and DeMixT could only be run for 2 tumor types with available normal samples (all selected tumor types except SKCM). DeMixT 3 and LinSeed were run using R v.3.6.1 and their respective R packages, CiberSortX was run 4 using its online web interface. Estimated tumor purity fractions were compared to values 5 computed by the TCGA pan-cancer consortium using the ABSOLUTE algorithm 6 (https://gdc.cancer.gov/about-data/publications/pancanatlas). 7 8
Database of ligand-receptor interactions 9
We obtained ~1400 ligand-receptors pairs supported by evidence in the literature as compiled Table  14 2. 15 16
Cancer-stroma gene expression deconvolution 17
We assume tumors to be comprised of cancer and stromal (any non-cancer) cells. Measured 18 bulk tumor mRNA abundance is then given by the sum of mRNA molecules derived from these 19 two compartments. Tumor mRNA expression ( "#$%&,( ) measured for a given gene in sample 20 i can then be expressed as: 
24
Here pi denotes the cancer cell proportion (tumor purity) in sample i, and ̅ -./-0& and ̅ 6"&%$.
25
are average expression levels for the gene in the cancer and stromal compartment (not 26 dependent on sample i), respectively. We make the simplifying assumption that these (non-27 negative) average compartment expression levels are constant across the set of tumors and 28 estimate them using non-negative least squares regression. 95%-confidence intervals and 29 standard deviations for the cancer and stroma point estimates are estimated using 30
bootstrapping. 31
Bulk tumor RNA-seq FPKM data was log-transformed, log2(X+1), before 32 deconvolution. It has previously been discussed whether mixed-tissue gene expression 33 deconvolution should be done using linear or log-transformed gene expression values(Shen-34
Orr et al., 2012; Zhong and Liu, 2012) . Firstly, we observed that the relationship between 35 tumor purity and raw bulk tumor gene expression was generally heteroscedastic: Across all 36 cancer types, tumor purity had overall stronger linear correlation with log-transformed RNA-1 seq gene expression data, as can be observed in deconvolution of known stromal-specific 2 genes (Suppl . Fig 2-5) . Secondly, we directly compared results for raw and log-transformed 3 data, and while the results were overall similar, we found that log-transformation provided 4 better separation between inferred cancer and stroma compartment gene expression for 5 known stromal genes (Suppl. Fig 15) , which is consistent with previous empirical analysis 6 (Shen-Orr et al., 2012). 7
We found that the equation above tended to misestimate stromal gene expression for 8 genes with somatic copy number alterations (CNA) affecting gene expression in a subset of 9 the samples (for example ERBB2 in HER2-positive breast tumors). We therefore used a 10 modified approach for such genes. We first identified genes with correlation between CNA 11 and mRNA expression (comparing expression for samples with diploid and non-diploid CNA, 12
Mann-Whitney U-test, P<1e-6, to account for multiple testing) in a given set of tumors, and 13 then estimated cancer and stromal compartment gene expression using a two-step approach. 14 Stromal compartment mRNA expression was first inferred using the above approach using 15 only samples with diploid copy number for the gene. We then used the inferred mean stroma 16 compartment expression, the measured mean tumor expression, and the mean purity of the 17 tumor samples to calculate the mean cancer compartment expression using the above 18
equation. 19
A limitation of TUMERIC is that the method estimates average cancer and stromal 20 compartment gene expression across a cohort of tumor samples. Since the stromal 21 compartment is a mix of many different types of cells, the averaged stromal expression 22 estimates therefore require careful interpretation. Furthermore, exploration of biologically 23 relevant between-sample variation in gene expression, not due to variation in tumor purity, 24 requires additional downstream analysis of the expression residuals. 25
26

Deconvolution of iTRAQ tumor protein abundance data 27
We obtained iTRAQ protein abundance data for BRCA and OV tumor types using CPTAC 28 consortium data available at cBioPortal (www.cbioportal.org). Bulk abundance profiles were 29 deconvolved into cancer and stroma compartment abundance profiles similar to the 30 procedures described for RNA-seq data above. Briefly, we have matched protein abundance 31 and consensus tumor purity data available for each tumor. We can therefore use the 32 consensus tumor purity estimates and NNLS to infer the (mean) abundance of individual 33 proteins in the cancer and stromal compartment, respectively. In our analysis we are only evaluating relative changes of individual LR complex 7 concentrations across samples or compartments. Since the dissociation constant cancels out 8 (present in numerator and denominator) when we compute relative concentrations (RC score 9 below) we can ignore the dissociation constant in downstream analysis. Our analysis depends 10 on multiple simplifying assumptions. We assume that compartment-level mRNA expression 11 estimates are reasonable proxies for ligand and receptor molar concentration at the site of 12 LR-complex formation. Additionally, we assume there is no external competition for individual 13 ligands and receptors of a given LR pair, or that these effects are constant across samples or 14
compartments. 15
To estimate the relative flow of signaling between cancer and stromal cell 16 compartments, we developed the Relative Crosstalk (RC) score. LR complex activity is first 17 approximated using the product of ligand and receptor gene expression inferred for the given 18 The normal term in the denominator is included to normalize for complex activity in normal 25 tissue, and this term is calculated directly from the observed gene expression levels in normal 26 tissue samples available for each tumor type in TCGA. 27 28
Gene-set enrichment analysis 29
To study genes differentially expressed between cancer and stromal compartments, we 30 performed GSEA (Subramanian et al., 2005) pre-ranked analysis of genes sorted by 31 differential expression (log fold-change) in the two compartments. We analyzed all hallmark 32 gene sets and used a FDR cut-off of 0.25 to determine gene sets with differential enrichment. 33 34
Immunohistochemistry (IHC) quantification analysis of Human Protein Atlas data 35
In order to quantify cancer and stromal cells expression of genes, we performed color 1 deconvolution of IHC images obtained from the Human Protein Atlas (proteinatlas.org) (Uhlen 2 et al., 2017) using the ImageJ software package and standard protocols (Schindelin et al., 3 2015) . Following manual selection and segmentation of cancer and stromal cells (without 4 knowledge of antibody staining), color intensities were measured with ImageJ, and DAB 5 (target), hematoxylin (cells), and complementary components were estimated. Average 6 antibody intensities were then estimated for the cancer and stromal compartment of a given 7 slide. Further technical details are provided in the supplementary methods. 8 9
RNA-ISH of breast cancer tissue 10
We obtained Formalin-Fixed Paraffin-Embedded (FFPE) breast cancer tissue slides for 2 11 luminal (ER+/PR+) and 2 triple negative basal-like breast tumors. In situ hybridization (ISH) 12 was performed using specific RNAScope (https://acdbio.com) probes to evaluate IL6ST and 13 SFRP1 RNA level and localization. The FFPE slides were deparaffinised, rehydrated, and 14 pretreated using the RNAScope Sample Preparation kit according to the manufacturer's 15 recommendations. The slides were incubated in target retrieval solution (#322000, Advanced 16
Cell Diagnostics) for 15 minutes at 97°C followed by a protease solution (#322330, Advanced 17
Cell Diagnostics) for 30 minutes at 40°C. RNAScope IL6ST (#447251) and SFRP1 (#429381-18 C2) target probe and RNAScope 2.5 HD Duplex Detection (Chromogenic) kit (#322430, 19
Advanced Cell Diagnostics) were applied to the slide according to the manufacturer's 20 instructions. RNA expression was quantified using two approaches. Firstly, according to the 21 manufacturer's instructions (TS 46-003), we segmented the Images using supervised machine 22 learning. Briefly, we used Fiji/ImageJ to train a 4-class random forest classifier to distinguish 23 regions with SFRP1 staining, IL6ST staining, nuclear regions, and background signal. We 24 used this model to segment all 8 images. We selected 5 cancer cell regions in each image 25 and recorded the mean probability for the SFRP1 and ILST6 staining classes in each region. 26
These staining probabilities were summarized (mean and standard deviation) across all 27 regions from the four images (2 patients) for the luminal and basal subtype, respectively. As 28 a second and different approach, we quantified IL6ST and SFRP1 mRNA expression in cancer 29 cells of basal and luminal breast cancer tissues using 3-channel color deconvolution. 30
Channels were specified for probe 1 (SFRP1), probe 2 (IL6ST), and background. Multiple 31 areas enriched for cancer cells were selected in each tissue slide and the optical density (OD) 32 was calculated for each area. The average and standard deviation of the OD for each gene 33 and tissue type was calculated. 34
35
Supplementary data 36
All code used to generate the figures and statistics of the paper is included in Supplementary 1 Data 1. Source code for Tumeric is attached as Supplementary data 2. RC scores and other 2 summary metrics for all analyzed ligand-receptor pairs are summarized in Supplementary 3 for each tumor sample (bottom panel). b) Inferred cancer and stroma compartment expression 8 levels for 280 known stromal-specific genes. c) Inferred cancer and stroma compartment 9 expression levels in melanoma (SKCM) for cancer and stroma specific genes previously 10 identified with melanoma scRNA-seq. d) Genes were ordered by inferred expression 11 difference between cancer and stroma compartments in each tumor type, and gene set 12 enrichment analysis (GSEA) was used to identify cancer and stroma enriched gene sets. e) 13
Protein expression was inferred for cancer and stroma compartments in (OV) and breast 14 (BRCA) cancer cohorts using iTRAQ protein quantification data and compared to deconvolved 15
RNA-seq expression data. f) Comparison of immunohistochemistry (IHC) and deconvolved 16
RNA-seq expression for a gene (S100A6) with highly variable cancer/stroma expression 17 across cancer types; error bars reflect standard deviations of the point estimates. Relative Crosstalk (RC) score approximates the relative flow of signaling in the four possible 4 directions between cancer and stromal cell compartments, including a bulk (non-deconvolved) 5 matched normal tissue reference. In the concrete example, a given ligand is expressed with 1, 6, 6 and 2 copies (receptor in 3, 1, and 1 copies) in cancer, stroma, normal cells, respectively. This 7 yields a stroma-to-cancer (S>C) RC score of 60%. d) Median RC score across the 20 solid tumor 8 types was estimated and plotted for each direction of signaling. e, f, g) RC scores for the 5 ligand-9 receptor pairs with highest median pan-cancer cancer-cancer autocrine e), cancer-stroma f), and 
